title: IGF-1 receptor transactivation mediates Src-dependent cortactin phosphorylation in response to angiotensin II.
abstract: Release of angiotensin II (Ang II) after vascular injury promotes tissue repair by stimulating phenotypic modulation of smooth muscle cells, which enables cell proliferation and migration. This process requires cytoskeleton remodeling, which involves cortactin, a scaffold protein that is phosphorylated by Src kinase in response to Ang II. Since insulin-like growth factor (IGF)-1 receptor transactivation mediates intracellular signals originating from the Ang II type 1 (AT1) receptor in a Src kinase-dependent manner, we examined whether IGF-1 receptor transactivation was also required for cortactin phosphorylation. Treatment of quiescent smooth muscle cells with Ang II resulted in both cortactin phosphorylation and its translocation to the plasma membrane. Both events were prevented by 1-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine (PP1), a Src kinase inhibitor, and by AG1024, an inhibitor of the IGF-1 receptor tyrosine kinase. Additionally, PP1 and AG1024 blocked the association of cortactin with actin-related protein (Arp) 3, an actin nucleation factor. These results indicate that Src kinase and the IGF-1 receptor kinase are necessary for activating cortactin. Phosphorylation of Src kinase in Ang II-treated cells was subsequently examined and was shown to be prevented by AG1024. Furthermore, Src kinase phosphorylation was blocked by inhibitors of protein kinase C (PKC), but not by inhibitors of phosphatidylinositol (PI) 3-kinase. These data establish that IGF-1 receptor transactivation is required for Src kinase-mediated cortactin phosphorylation and cytoskeletal reorganization in response to Ang II.
authors.affiliation: Department of Physiology, University of Manitoba, Winnipeg, Canada. peterz@sbrc.ca
authors.forename: Peter
authors.initials: P
authors.lastname: Zahradka
authors.forename: Benjamin
authors.initials: B
authors.lastname: Storie
authors.forename: Brenda
authors.initials: B
authors.lastname: Wright
mesh_terms: D051378:Actin-Related Protein 3 / Q000235:genetics / Q000378:metabolism; D000804:Angiotensin II / Q000494:pharmacology*; D000818:Animals; D015153:Blotting, Western; D051356:Cortactin / Q000378:metabolism*; D005455:Fluorescent Antibody Technique; D047468:Immunoprecipitation; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D011493:Protein Kinase C / Q000378:metabolism; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000378:metabolism; D013552:Swine; D015533:Transcriptional Activation; D020032:Tyrphostins / Q000494:pharmacology; D019061:src-Family Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D051378:Actin-Related Protein 3; D051356:Cortactin; D020032:Tyrphostins; C447031:tyrphostin AG 1024; D000804:Angiotensin II; D019869:Phosphatidylinositol 3-Kinases; D017526:Receptor, IGF Type 1; D020797:Receptor, Platelet-Derived Growth Factor beta; D019061:src-Family Kinases; D011493:Protein Kinase C